Keros Therapeutics 향후 성장

Future 기준 점검 0/6

Keros Therapeutics 의 수익과 수익은 각각 연간 23.2% 및 35.4% 감소할 것으로 예상됩니다 while EPS는 연간 34% 만큼 쇠퇴할 것으로 예상됩니다.

핵심 정보

-35.4%

이익 성장률

-34.05%

EPS 성장률

Biotechs 이익 성장	22.5%
매출 성장률	-23.2%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	05 Jan 2026

최근 향후 성장 업데이트

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Nov 18

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Aug 21

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

May 29

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

May 14

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

May 09

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

이익 및 매출 성장 예측

NasdaqGM:KROS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	56	-150	-131	N/A	9
12/31/2027	15	-171	-135	N/A	9
12/31/2026	13	-146	-127	N/A	10
12/31/2025	246	82	82	N/A	10
9/30/2025	247	64	87	89	N/A
6/30/2025	233	19	53	55	N/A
3/31/2025	215	4	43	45	N/A
12/31/2024	4	-187	-163	-161	N/A
9/30/2024	1	-182	-143	-140	N/A
6/30/2024	0	-168	-146	-144	N/A
3/31/2024	0	-160	-137	-135	N/A
12/31/2023	0	-153	-127	-125	N/A
9/30/2023	0	-142	-123	-120	N/A
6/30/2023	N/A	-127	-113	-111	N/A
3/31/2023	N/A	-116	-105	-103	N/A
12/31/2022	N/A	-105	-71	-70	N/A
9/30/2022	20	-82	-69	-68	N/A
6/30/2022	20	-79	-59	-58	N/A
3/31/2022	20	-67	-54	-53	N/A
12/31/2021	20	-59	-63	-62	N/A
9/30/2021	0	-61	-51	-51	N/A
6/30/2021	0	-53	-48	-47	N/A
3/31/2021	N/A	-49	-40	-39	N/A
12/31/2020	N/A	-45	-37	-37	N/A
9/30/2020	3	-39	-35	-34	N/A
6/30/2020	5	-31	-27	-26	N/A
3/31/2020	8	-23	-22	-22	N/A
12/31/2019	10	-14	-16	-16	N/A
12/31/2018	10	-2	N/A	7	N/A

애널리스트 향후 성장 전망

수입 대 저축률: KROS 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -35.4%).

수익 vs 시장: KROS 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -35.4%).

고성장 수익: KROS 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: KROS 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -23.2%).

고성장 매출: KROS 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -23.2%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: KROS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/02/01 04:57
종가	2026/01/30 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Keros Therapeutics, Inc.는 18명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Zemansky	BofA Global Research
Corinne Johnson	Goldman Sachs
Andrew Fein	H.C. Wainwright & Co.

Keros Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.1% to US$88.11

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Consensus EPS estimates fall by 18%

Price target increased to US$98.75

Price target increased to US$94.00

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. (NasdaqGM:KROS) announces an Equity Buyback for 10,950,165 shares, representing 35.94% for $194.37 million.

Keros Therapeutics, Inc. Announces Board and Committee Changes, Effective October 15, 2025

Keros Therapeutics, Inc. Presents Additional Clinical Data from Its Ker-065 Program At the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

ADAR1 Sends Open Letter to Keros Board of Directors

Keros Therapeutics, Inc. Announces Management Changes, Effective August 18, 2025

Keros Therapeutics, Inc. Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Index

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Keros Therapeutics, Inc. Announces Corporate Restructuring

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics, Inc., Annual General Meeting, Jun 04, 2025

Keros Therapeutics, Inc. Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely